tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Katherine Breedis, 8 are a BUY (100%).
Analyst Katherine Breedis, currently employed carries an average stock price target met ratio of 25% that have a potential upside of 29.96% achieved within 1059 days. Previously, Katherine Breedis worked at STIFEL.
Katherine Breedis’s has documented 14 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on VYGR, Voyager Therapeutics at 28-Jul-2017.
Analyst best performing recommendations are on GILD (GILEAD SCIENCES).
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$125
$35.6 (39.82%)
$95
3 days ago
(14-Nov-2024)
15/16 (93.75%)
$33.11 (36.03%)
1083
Buy
$92
9 days ago
(08-Nov-2024)
6/6 (100%)
$18.74 (25.58%)
1316
Buy
$105
$15.6 (17.45%)
$95
10 days ago
(07-Nov-2024)
1/4 (25%)
$8.19 (8.46%)
57
Hold
$81
$-8.4 (-9.40%)
$75
10 days ago
(07-Nov-2024)
61/69 (88.41%)
$-15.81 (-16.33%)
1527
Hold
$95
$5.6 (6.26%)
$80
10 days ago
(07-Nov-2024)
15/27 (55.56%)
$-1.81 (-1.87%)
1178
What Year was the first public recommendation made by Katherine Breedis?
